![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/03/2892487/0/en/7-Hills-Pharma-Receives-4-7MM-Grant-to-Advance-First-in-class-Cell-Gene-Therapy-Technology-into-the-Clinic.html
https://www.globenewswire.com/news-release/2023/05/22/2673708/0/en/7-Hills-Pharma-Surpasses-25MM-Milestone-in-Nondilutive-Funding.html
https://www.globenewswire.com/news-release/2022/08/01/2489170/0/en/7-Hills-Pharma-Receives-3MM-SBIR-Grant-from-NIAID-to-Accelerate-Novel-Vaccine-Combination-Against-Chagas-Disease.html
https://www.globenewswire.com/news-release/2022/06/09/2460188/0/en/7-Hills-Pharma-Expands-Pioneering-Patent-Portfolio-With-New-Claims-Covering-Innovative-Combination-Therapies.html
https://www.globenewswire.com/news-release/2022/05/18/2446484/0/en/New-Study-Demonstrates-Integrin-Activation-Can-Bring-the-Heat-to-Cold-Melanoma-Tumors.html
https://www.globenewswire.com/news-release/2022/03/08/2399494/0/en/7-Hills-Pharma-s-Clinical-stage-Novel-Immunostimulant-7HP349-Granted-FDA-Fast-Track-Designation-for-Anti-PD-1-resistant-Metastatic-Melanoma.html
https://www.globenewswire.com/news-release/2021/11/01/2324758/0/en/7-Hills-Pharma-Announces-the-Completion-of-a-Landmark-Phase-I-Trial-of-Immunostimulant-to-Improve-Immuno-Oncology-Drugs-COVID-19-and-Influenza-Vaccines.html
https://www.globenewswire.com/news-release/2020/11/09/2122467/0/en/7-Hills-Pharma-Announces-First-Healthy-Volunteers-Dosed-in-Landmark-Phase-1-Trial-of-Immunostimulant-to-Improve-Immuno-Oncology-Drugs-COVID-19-and-Influenza-Vaccines.html
https://www.globenewswire.com/news-release/2020/08/04/2072199/0/en/7-Hills-Pharma-Awarded-Pioneering-Patent-Estate-Covering-Integrin-Activators-to-Improve-Effectiveness-of-Immunotherapies.html#:~:text=HOUSTON%2C%20Aug.%2004%2C%202020,Office%20(USPTO)%20on%20four%20patents
https://www.globenewswire.com/news-release/2020/07/07/2058365/0/en/7-Hills-Pharma-Announces-Positive-Data-With-Oral-Immunostimulant-to-Improve-Effectiveness-of-COVID-19-Vaccines.html